I
Ishwarlal Jialal
Researcher at Veterans Health Administration
Publications - 378
Citations - 25377
Ishwarlal Jialal is an academic researcher from Veterans Health Administration. The author has contributed to research in topics: Diabetes mellitus & Metabolic syndrome. The author has an hindex of 90, co-authored 369 publications receiving 23761 citations. Previous affiliations of Ishwarlal Jialal include California Northstate University College of Pharmacy & University of Texas Health Science Center at San Antonio.
Papers
More filters
Journal ArticleDOI
Demonstration That C-Reactive Protein Decreases eNOS Expression and Bioactivity in Human Aortic Endothelial Cells
TL;DR: C-reactive protein causes a direct reduction in eNOS expression and bioactivity in HAECs, further supporting its role in atherogenesis.
Journal ArticleDOI
Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Therapy on High Sensitive C-Reactive Protein Levels
Ishwarlal Jialal,D. Stein,David S. Balis,Scott M. Grundy,Beverley Adams-Huet,Sridevi Devaraj +5 more
TL;DR: Data support an anti-inflammatory effect of these drugs on levels of high-sensitive CRP in patients with combined hyperlipidemia, and there was no relationship between reductions in hs-CRP and LDL cholesterol.
Journal ArticleDOI
C-Reactive Protein Increases Plasminogen Activator Inhibitor-1 Expression and Activity in Human Aortic Endothelial Cells Implications for the Metabolic Syndrome and Atherothrombosis
TL;DR: This study makes the novel observation that CRP induces PAI-1 expression and activity in HAECs and thus has implications for both the metabolic syndrome and atherothrombosis.
Journal ArticleDOI
C-Reactive Protein: Risk Marker or Mediator in Atherothrombosis?
TL;DR: In conclusion, CRP is a risk marker for cardiovascular disease and, based on future studies, could emerge as a mediator in atherogenesis.
Journal ArticleDOI
Vitamin e, oxidative stress, and inflammation
TL;DR: Dietary micronutrients having anti-inflammatory and antioxidant properties and AT (at the appropriate dose and form) could have beneficial effects on cardiovascular disease in a high-risk population.